Background: Combined oral modified-release oxycodone-naloxone may reduce opioid-induced postoperative gut dysfunction. This study examined the feasibility of a randomized trial of oxycodone-naloxone within the context of enhanced recovery for laparoscopic colorectal resection. 
Introduction
As multimodal enhanced recovery pathways have been implemented in laparoscopic and open colorectal surgery, there has been recognition that delayed return of gut function represents one of the main barriers to maximizing the benefits of modern surgical techniques vomiting, constipation or abdominal distension sufficient to prevent resumption of adequate postoperative oral nutritional intake. Treatment comprises fasting, prolongation of intravenous fluid therapy and nasogastric tube insertion. Although self-limiting in most cases, it can prolong hospital admission by a number of days, despite the absence of other postoperative complications, increasing healthcare costs 1 .
Opioids are the mainstay of postoperative analgesic regimens after abdominal surgery and are highly effective in achieving adequate pain control. However, opioids contribute to impaired gut function by reducing normal forward propulsion and increasing non-propulsive gut spasm 4, 5 . Targinact ® (Napp Pharmaceuticals, Cambridge, UK) is a combination of modified-release oxycodone hydrochloride and naloxone hydrochloride (an opioid receptor antagonist), designed to reduce constipation in patients with chronic pain requiring long-term opioids.
Oral naloxone has minimal systemic availability (high first-pass hepatic metabolism), confining its local action to the gut to reduce opiate inhibition of gut motility without systemic effects. Oxycodone-naloxone has been shown to provide comparable analgesia to other opioid analgesics in patients with chronic severe pain whilst reducing the unwanted side-effect of constipation 6, 7 . Whether it has the same beneficial effect on constipation in the acute pain setting, and whether there would be a more rapid return of overall gastrointestinal function in the postoperative setting, is not known. The trial was undertaken as a pilot study for the following reasons: to estimate effect size (having no information a priori on which to base a sample size calculation); to refine endpoint definition of return of gut function; and to assess variation in protocol compliance and other practical aspects of running a clinical trial within a complex intervention in a busy National Health Service (NHS) hospital. The primary endpoint was feasibility, assessed by recruitment and retention (number of patients screened and/or consented), and compliance with the intervention. The secondary endpoints were regarded as exploratory to inform design of future trials of return of gut function after surgery, and included time to tolerance of diet and time to passage of first flatus and faeces 3, 8 .
Methods
Gut function comprises the interaction of many complex physiological functions and there is no universal definition to confirm its return after major abdominal surgery. Resumption of normal gut function requires patients to have the desire to eat, sufficiently low levels of nausea or vomiting to ingest food, and evidence of return of lower gastrointestinal transit, evidenced by passage of flatus or faeces, with the former usually preceding. Thus, a number of positive and negative endpoint definitions exist, including tolerance of diet, independence from intravenous fluids, passage of flatus, bowel movement, absence of severe nausea and vomiting, and nasogastric tube insertion 8 -10 . None of these measures is satisfactory in isolation.
Data were recorded to define the return of gut function positively and negatively after laparoscopic colectomy. The prestudy composite definition of return of gut function was toleration of diet, absence of severe nausea/vomiting (postoperative nausea and vomiting (PONV) score of 4 or less 11 ), and passage of either flatus or faeces, reflecting seminal work in this area by previous investigators 3, 8, 12 .
Studying the impact on postoperative outcomes of a single component within a complex intervention such as colonic surgery is challenging. Minimizing variation by the application of a consistent experimental model is fundamental to enabling robust conclusions to be drawn; ideally, all aspects of treatment would be identical for each patient apart from the intervention being studied. This is difficult to achieve across all aspects of patient selection, anaesthesia, surgical intervention and perioperative care within a busy NHS hospital setting. Therefore, the study included only colonic resections that could be carried out by different surgeons with a consistent technique. A standard anaesthetic protocol and perioperative patient care pathway based on enhanced recovery after surgery principles was agreed by anaesthetic and surgical teams, and its implementation was monitored by the study team 13 .
Study design and participants
A phase II, randomized, open-label trial was conducted (ClinicalTrials.gov: NCT02109640) to compare modified-release oxycodone-naloxone (intervention) with modified-release oxycodone (control). Patients were recruited between 1 December 2014 and 12 August 2015 from those scheduled for elective laparoscopic segmental colonic resection under the care of one of 11 specialist colorectal surgeons at the Lothian Colorectal Surgery Unit, Western General Hospital, Edinburgh, UK. Patients were identified from all patients being scheduled for elective segmental colonic resection, and potential eligibility for study inclusion was confirmed with the responsible surgeon. Enrolment and consent to participate was undertaken at hospital visits required as part of the normal patient pathway (outpatient clinics, preoperative assessments).
Exclusions were pregnancy, inability to give informed consent, age below 18 years, regular opioid analgesic prescription, opiate dependence, intolerance or allergy to oxycodone-naloxone or oxycodone, total rectal resection, planned stoma or additional intraoperative procedure. At baseline, patients were assessed in terms of: BMI; waist/hip ratio 14 ; Simplified Nutritional Appetite Questionnaire (SNAQ) 15 ; quality of recovery score (QoRS) 16 , Portsmouth POSSUM 17 , and Apfel score for prediction of PONV 18 .
The protocol was approved by the East of Scotland Research Ethics Service and written informed consent was obtained from all patients. The trial was performed in compliance with International Conference on Harmonisation Good Clinical Practice (ICH-GCP) guidelines and the Helsinki Declaration.
Randomization
Eligible patients were randomized before surgery to receive intervention or control drug (allocation ratio 1 : 1) using sealed envelopes stratified by left or right colectomy, created independently by the study statistician. The randomization sequence was generated with the block method, using blocks of six and eight to disguise the pattern. Separate schedules were generated for left and right colonic operations. The number of randomizations generated was slightly larger than the sample size required in order that the last randomization would not be 'guessable'. The statistician was blinded to which group was allocated to intervention and which to control. Randomization was carried out by the principal or chief investigator opening the next envelope in a numbered sequence in the presence of a research nurse, after informed consent had been obtained, approximately 1-7 days before the intended date of operation. The first (preoperative) dose of the study drug or control was then prescribed for the date of surgery and ordered from the hospital pharmacy. Treatment allocation was not blinded to the patient, clinical staff or research study staff as overencapsulation of the study drugs proved prohibitively expensive.
Protocol
A key feature of the study design was that patients were given the first dose of oxycodone-naloxone (10 mg) or oxycodone (10 mg) 1-2 h before induction of anaesthesia. It was postulated that giving oxycodone-naloxone before administration of systemic opioids during anaesthesia would maximize any potential benefit of the gut naloxone component in reducing gut dysfunction. Patients were managed using a standard perioperative care pathway based on enhanced recovery principles in order to maintain consistency of perioperative care 13 . Eleven surgeons and ten anaesthetists participated in the study. Surgery was undertaken by colorectal specialists, all of whom had undertaken more than 100 laparoscopic colonic resections before the study and perform 30-40 laparoscopic colonic resections per year.
Standard operative technique was agreed between the participating surgeons. Right hemicolectomy was undertaken using a four-port technique, ligating and dividing the proximal ileocolic/right colic vessels to achieve radical lymphadenectomy and extracting the colon via a small periumbilical incision to undertake resection and end-to-end sutured anastomosis. Left colectomy was undertaken using a four-or five-port technique, with routine splenic flexure mobilization, high ligation of the inferior mesenteric artery and vein, extraction of the specimen through a short Pfannenstiel incision and stapled transanal intracorporeal anastomosis. To achieve a consistent operation for evaluating the study drug, patients undergoing procedures converted to open surgery or requiring an unplanned stoma were withdrawn.
Anaesthesia comprised a single intrathecal injection of diamorphine (0⋅8 mg) plus 3 ml bupivacaine 0⋅25 per cent, induction with propofol (1-2 mg/kg) and remifentanil Oral oxycodone-naloxone (5-20 mg) or oxycodone (5-20 mg) 12-hourly was continued from the evening of surgery. All patients received oral paracetamol (1 g four times daily). Non-steroidal anti-inflammatory drugs were not used routinely. Pain scores were assessed daily by the acute pain team according to existing unit protocols.
Perioperative management was delivered according to a defined protocol, which included: minimal preoperative fasting time; preoperative oral fluid and carbohydrate loading; early discontinuation of intravenous fluids (day 1); early discontinuation of systemic and/or oral opioids; immediate resumption of oral nutrition as tolerated; and defined daily mobilization goals. Patients were deemed fit for discharge if they met the following criteria: tolerating diet and fluids without requirement for intravenous fluids, passage of either flatus or faeces, independently mobile, pain controlled with oral analgesia, no medical contraindication to discharge, and willingness to go home.
Outcomes
The objective was to learn about all the parameters required to design a definitive trial if the authors were persuaded that such a definitive trial was necessary and feasible. Therefore, the primary endpoints were chosen to assess the feasibility of studying the effect of a specific perioperative intervention intended to improve return of postoperative gut function (in this case oxycodone-naloxone). Recruitment was assessed by the proportion of patients screened versus those consented. Retention was determined by documenting the attrition rate and the reasons for attrition.
The main secondary outcome was the return of gut function on the third postoperative day. Protocol definition of return of gut function was a composite endpoint measured on day 3 after surgery comprising each of the following: toleration of diet (3 consecutive light meals), PONV score of 4 or less, and passage of either flatus or faeces. Outcomes were documented by study nurses or a research fellow at a daily morning visit to each patient. Before the first randomized patient, data collection was tested on five 'dummy' patients to evaluate study documentation and review the utility of data recording and definitions. The day of operation was day 0; day 3 was the third day after the day of surgery.
Other secondary outcome measures comprised the following patient-reported outcome measures: overall benefit of analgesia score (OBAS) 19 , PONV score 11 , QoRS 16 , oral nutritional intake (patient diary), daily opioid consumption, time to first flatus and time to first bowel movement. The study team did not participate in deciding on date of discharge, which was left to the clinical team. Complications were recorded using a severity scale until 30 days after surgery 20 . Protocol compliance was measured based on implementation of the following core perioperative interventions: single spinal dose of diamorphine; 12-h lidocaine infusion; cessation of morphine PCA on day 1 (the first postoperative day); cessation of intravenous fluids on day 1.
Statistical analysis
As this was a pilot study, a power calculation was not performed. A sample size of 50 evaluable patients was chosen as an achievable recruitment target within the specified study duration of 1 year, and it was felt that this would be sufficient to estimate reliably the study performance metrics (such as recruitment rate) and likewise give adequate insight into the parameters needed (such as the variability, and the prevalence of delayed return of gut function and prolonged POI) to inform a sample size calculation for a definitive full multicentre UK-wide clinical and cost-effectiveness study.
Analyses of the data included Fisher's exact test for categorical data (owing to the small numbers in some of the cells), and Student's t test, with log transformation where appropriate. Estimates of differences in proportions and means were also calculated. The randomized groups were compared for a number of clinical measures, and in general a comment is made where there was little or no difference between the groups. However, as a pilot/feasibility study, the sample size was insufficient to rule out what might be important clinical differences, as evidenced by the large width of the 95 per cent confidence intervals (c.i.) around the point estimates between randomized group differences. As all of these analyses are descriptive, no adjustment was made for multiple comparisons, so caution should be exercised when interpreting the data.
Statistical analysis was performed using SPSS ® version 19.0 (IBM, Armonk, New York, USA). The trial statistician was blinded to treatment allocation for data analysis. A two-sided 5 per cent significance level was applied throughout. All data for the variables included were complete for all patients. However, unless demonstrated otherwise, data would have been assumed to be missing at random.
Results

Primary outcomes
Eighty-two patients were screened over an 8-month period, resulting in 62 patients being randomized (Fig. 1) . The recruitment rate (screened versus consented) was 76 per cent (62 of 82). The main reason for non-recruitment was failure to meet eligibility criteria. Patients randomized but not analysed were withdrawn owing to: development of protocol-specified ineligibility (change of planned operation in 3 patients; emergency surgery before the planned date of elective surgery in 1 patient); conversion to open surgery in three patients; eligibility violation in one patient (chronic opioid use); decision by anaesthetist to deviate substantially from defined protocol (for example epidural) in three patients; and a fundamental protocol violation (first dose of the study drug not given before surgery) in one patient (Fig. 1) . Study data were not collected for these patients. Thereafter, all patients who received the allocated intervention (27 in the oxycodone-naloxone arm, 23 in the oxycodone arm) had 100 per cent follow-up and were included in the analysis, referred to hereafter as the modified intention-to-treat population. Demographic and clinical characteristics of this population are shown in Table 1 .
Secondary outcomes
The numbers of patients achieving return of individual components of gut function by postoperative day 3 and 4 are shown in Table 2 . Day of return of gut function based on the prespecified composite endpoint definition of tolerating diet, passage of either flatus or faeces and PONV score of 4 or less is shown in Fig. 2 . The quality of analgesia and overall recovery assessed by OBAS and QoRS were similar (Fig. 3) . Time to first bowel movement was reduced in the oxycodone-naloxone group (Table 3) There was no clinically notable or statistically significant difference in other secondary outcome measures.
Complications
There were no suspected unexpected serious adverse reactions or serious adverse events attributable to the study drug. Three patients were readmitted urgently. There were two major complications in the intervention arm of the study: one intra-abdominal collection was drained percutaneously and one (day 4) anastomotic dehiscence required reoperation, repair and proximal diversion. There were no major complications in the control arm.
Protocol compliance
Forty-seven patients (94 per cent) received the single-shot spinal analgesia. Overall, 46 patients (92 per cent) received intravenous lidocaine; intravenous fluid was withdrawn per protocol in 45 (90 per cent) of 50 patients and had to be reinstituted owing to excessive nausea or intolerance of oral intake in 16 (32 per cent) of 50 patients. There was no difference in the distribution of these patients between the study arms ( Table 4 ). The urinary catheter was 
Discussion
The trial demonstrated that it is feasible to assess a novel perioperative intervention in the context of postoperative gut function using a consistent multimodal enhanced recovery pathway. The rate of recruitment and retention was good. The main reason for ineligibility was regular opioid use, reflecting the relatively elderly patients typical of colorectal practice. The attrition rate was an unanticipated consequence of the study design, in which the first dose of the study drug was given before surgery to maximize benefit. A more conventional design in which patients were randomized after completion of the operation might have resulted in lower attrition. In a future definitive study using the current design, all patients randomized would be included in analysis (testing the policy of treating rather than the drug itself). Overall length of hospital stay, gut function recovery times, event rate (POI) and complications were comparable with contemporary laparoscopic colectomy data 21, 22 . In contrast, the cohort was a decade older and cancer was the indication for surgery in a much greater number than in those reports. Excessive intravenous fluid administration was avoided, most patients were converted to oral analgesia on day 1 and independent mobilization was restored by day 2. The surgical intervention in the modified intention-to-treat population was consistent with protocol. Minor deviations from the anaesthetic protocol reflected the real-world nature of the study, for instance spinal osteoarthritis preventing spinal analgesia injection or early termination of intravenous lidocaine infusion owing to lack of high-dependency monitoring.
No patient relapsed once the composite endpoint definition of return of gut function had been achieved, and no patient was discharged before it was fulfilled. However, the PONV score did not provide additional discrimination to a definition of return of gut function comprising tolerance of diet and passage of flatus or faeces. Hence this study supports the GI-3 definition of return of gut function (tolerance of diet plus passage of flatus or bowel movement) as the appropriate endpoint for future studies 12,23 -25 .
Analgesia using oxycodone-naloxone appeared to be at least equivalent in efficacy to modified-release oxycodone; indeed, total opioid consumption was 20 per cent lower in the oxycodone-naloxone group. In addition, patients in the oxycodone-naloxone group had a shorter time to first bowel movement. These observations are biologically plausible: reduced inhibition of lower gastrointestinal function is the modus operandi of the study drug. Earlier defaecation may have contributed to lower total opioid consumption in the oxycodone-naloxone arm; it appeared that most of the difference in opioid consumption between the groups occurred after day 3 ( Table 3 ). Based on these data, to detect a difference of around 16 mg, assuming a common standard of about 40 mg (an effect size of 0⋅4) within this population, a study of approximately 300 participants would be needed (using a two-sample t test with 90 per cent power at a 5 per cent level of significance, and allowing for 15 per cent loss to follow-up). A study of about 300 patients would also be required to detect the difference observed in this study in time to first bowel movement (by 100 h (day 4) approximately 40 per cent of patients in the control group compared with 60 per cent of those in the intervention group had defaecated (Fig. 5) , an effect size of 20 per cent, using a comparison of proportions with 90 per cent power at a 5 per cent level of significance, and allowing for 15 per cent loss to follow-up).
Blinding was not undertaken in this study as the budget would not extend to commercial overencapsulation of controlled drugs. Investigator bias was minimized by the majority of outcome measures being patient-reported and non-involvement of the study team in clinical care (including analgesic assessment and prescription). The statistician was blinded to treatment allocation throughout. Double-blinding of a future study would be achievable within this model.
There was a considerable interval between passage of flatus and first bowel movement. Routine laxation was not part of the study protocol and might have reduced this interval, but adequate consensus on this point could not be agreed by participating surgeons, reflecting the limited evidence 26 .
Despite consistently implementing a modern enhanced recovery study protocol in one of the more straightforward colorectal surgery subgroups (laparoscopic segmental colectomy, no stomas, no low rectal dissection), gut function had not returned by day 3 in a substantial number of patients. Although there was a possible beneficial effect of oxycodone-naloxone on analgesia and time to first bowel movement, the combination drug did not alter the overall postoperative return of gut function in this study.
